These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 29273624)

  • 1. Enhancer transcription reveals subtype-specific gene expression programs controlling breast cancer pathogenesis.
    Franco HL; Nagari A; Malladi VS; Li W; Xi Y; Richardson D; Allton KL; Tanaka K; Li J; Murakami S; Keyomarsi K; Bedford MT; Shi X; Li W; Barton MC; Dent SYR; Kraus WL
    Genome Res; 2018 Feb; 28(2):159-170. PubMed ID: 29273624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene regulatory pattern analysis reveals essential role of core transcriptional factors' activation in triple-negative breast cancer.
    Min L; Zhang C; Qu L; Huang J; Jiang L; Liu J; Pinello L; Yuan GC; Shou C
    Oncotarget; 2017 Mar; 8(13):21938-21953. PubMed ID: 28423538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer.
    Liu YR; Jiang YZ; Xu XE; Yu KD; Jin X; Hu X; Zuo WJ; Hao S; Wu J; Liu GY; Di GH; Li DQ; He XH; Hu WG; Shao ZM
    Breast Cancer Res; 2016 Mar; 18(1):33. PubMed ID: 26975198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of activated enhancers and linked transcription factors in breast, prostate, and kidney tumors by tracing enhancer networks using epigenetic traits.
    Rhie SK; Guo Y; Tak YG; Yao L; Shen H; Coetzee GA; Laird PW; Farnham PJ
    Epigenetics Chromatin; 2016; 9():50. PubMed ID: 27833659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Super-enhancer acquisition drives oncogene expression in triple negative breast cancer.
    Raisner R; Bainer R; Haverty PM; Benedetti KL; Gascoigne KE
    PLoS One; 2020; 15(6):e0235343. PubMed ID: 32584896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LncRNA-mediated regulation of
    Tariq A; Hao Q; Sun Q; Singh DK; Jadaliha M; Zhang Y; Chetlangia N; Ma J; Holton SE; Bhargava R; Lal A; Prasanth SG; Prasanth KV
    RNA; 2020 Feb; 26(2):175-185. PubMed ID: 31690584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissecting the heterogeneity of the alternative polyadenylation profiles in triple-negative breast cancers.
    Wang L; Lang GT; Xue MZ; Yang L; Chen L; Yao L; Li XG; Wang P; Hu X; Shao ZM
    Theranostics; 2020; 10(23):10531-10547. PubMed ID: 32929364
    [No Abstract]   [Full Text] [Related]  

  • 8. Defining super-enhancer landscape in triple-negative breast cancer by multiomic profiling.
    Huang H; Hu J; Maryam A; Huang Q; Zhang Y; Ramakrishnan S; Li J; Ma H; Ma VWS; Cheuk W; So GYK; Wang W; Cho WCS; Zhang L; Chan KM; Wang X; Chin YR
    Nat Commun; 2021 Apr; 12(1):2242. PubMed ID: 33854062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aberrant activation of CYR61 enhancers in colorectal cancer development.
    Xie L; Song X; Lin H; Chen Z; Li Q; Guo T; Xu T; Su T; Xu M; Chang X; Wang LK; Liang B; Huang D
    J Exp Clin Cancer Res; 2019 May; 38(1):213. PubMed ID: 31118064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. microRNA-761 induces aggressive phenotypes in triple-negative breast cancer cells by repressing TRIM29 expression.
    Guo GC; Wang JX; Han ML; Zhang LP; Li L
    Cell Oncol (Dordr); 2017 Apr; 40(2):157-166. PubMed ID: 28054302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion.
    Bayraktar R; Ivan C; Bayraktar E; Kanlikilicer P; Kabil NN; Kahraman N; Mokhlis HA; Karakas D; Rodriguez-Aguayo C; Arslan A; Sheng J; Wong S; Lopez-Berestein G; Calin GA; Ozpolat B
    Clin Cancer Res; 2018 Sep; 24(17):4225-4241. PubMed ID: 29748184
    [No Abstract]   [Full Text] [Related]  

  • 12. Comprehensive Analysis of Differentially Expressed Profiles of lncRNAs/mRNAs and miRNAs with Associated ceRNA Networks in Triple-Negative Breast Cancer.
    Yang R; Xing L; Wang M; Chi H; Zhang L; Chen J
    Cell Physiol Biochem; 2018; 50(2):473-488. PubMed ID: 30308479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The hyper-activation of transcriptional enhancers in breast cancer.
    Li QL; Wang DY; Ju LG; Yao J; Gao C; Lei PJ; Li LY; Zhao XL; Wu M
    Clin Epigenetics; 2019 Mar; 11(1):48. PubMed ID: 30867030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
    Kren BT; Unger GM; Abedin MJ; Vogel RI; Henzler CM; Ahmed K; Trembley JH
    Breast Cancer Res; 2015; 17():19. PubMed ID: 25837326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOXM1 transcriptionally regulates expression of integrin β1 in triple-negative breast cancer.
    Hamurcu Z; Kahraman N; Ashour A; Ozpolat B
    Breast Cancer Res Treat; 2017 Jun; 163(3):485-493. PubMed ID: 28361350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternatively Constructed Estrogen Receptor Alpha-Driven Super-Enhancers Result in Similar Gene Expression in Breast and Endometrial Cell Lines.
    Bojcsuk D; Nagy G; Bálint BL
    Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32120995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computational Approaches for Mining GRO-Seq Data to Identify and Characterize Active Enhancers.
    Nagari A; Murakami S; Malladi VS; Kraus WL
    Methods Mol Biol; 2017; 1468():121-38. PubMed ID: 27662874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. miR-17-5p suppresses cell proliferation and invasion by targeting ETV1 in triple-negative breast cancer.
    Li J; Lai Y; Ma J; Liu Y; Bi J; Zhang L; Chen L; Yao C; Lv W; Chang G; Wang S; Ouyang M; Wang W
    BMC Cancer; 2017 Nov; 17(1):745. PubMed ID: 29126392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upregulation of MGP by HOXC8 promotes the proliferation, migration, and EMT processes of triple-negative breast cancer.
    Gong C; Zou J; Zhang M; Zhang J; Xu S; Zhu S; Yang M; Li D; Wang Y; Shi J; Li Y
    Mol Carcinog; 2019 Oct; 58(10):1863-1875. PubMed ID: 31264274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrative epigenomic and high-throughput functional enhancer profiling reveals determinants of enhancer heterogeneity in gastric cancer.
    Sheng T; Ho SWT; Ooi WF; Xu C; Xing M; Padmanabhan N; Huang KK; Ma L; Ray M; Guo YA; Sim NL; Anene-Nzelu CG; Chang MM; Razavi-Mohseni M; Beer MA; Foo RSY; Sundar R; Chan YH; Tan ALK; Ong X; Skanderup AJ; White KP; Jha S; Tan P
    Genome Med; 2021 Oct; 13(1):158. PubMed ID: 34635154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.